Hologic Stock: Is Wall Street Bullish or Bearish?
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 15 2025
0mins
Source: NASDAQ.COM
Company Overview and Performance: Hologic, Inc., a women's healthtech company based in Marlborough, Massachusetts, has seen its stock decline 26.8% over the past year, underperforming both the S&P 500 and the SPDR S&P Health Care Equipment ETF. Despite slightly better-than-expected Q2 earnings, the stock dropped 5.5% due to lowered fiscal 2025 EPS guidance.
Analyst Ratings and Future Outlook: The consensus rating for Hologic among analysts is a "Moderate Buy," with a mean price target of $70.20 indicating a potential upside of 26.8%. However, this sentiment has softened compared to three months ago, with fewer analysts recommending a "Strong Buy."
Analyst Views on XHE
Wall Street analysts forecast XHE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for XHE is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 89.655
Low
Averages
High
Current: 89.655
Low
Averages
High
No data
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
